189 related articles for article (PubMed ID: 33807057)
1. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
Chang HP; Cheung YK; Shah DK
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807057
[TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
3. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
Chang HP; Cheung YK; Liu S; Shah DK
Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
5. A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs.
Singh AP; Guo L; Verma A; Wong GG; Shah DK
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30823607
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
[TBL] [Abstract][Full Text] [Related]
10. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
11. Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.
Singh AP; Shah DK
Drug Metab Dispos; 2017 Nov; 45(11):1120-1132. PubMed ID: 28821484
[TBL] [Abstract][Full Text] [Related]
12. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
[TBL] [Abstract][Full Text] [Related]
13. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera.
Pei M; Liu T; Ouyang L; Sun J; Deng X; Sun X; Wu W; Huang P; Chen YL; Tan X; Liu X; Zhu P; Liu Y; Wang D; Wu J; Wang Q; Wang G; Gong L; Qin Q; Wang C
J Pharm Anal; 2022 Aug; 12(4):645-652. PubMed ID: 36105165
[TBL] [Abstract][Full Text] [Related]
15. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.
Chang HP; Le HK; Shah DK
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111619
[TBL] [Abstract][Full Text] [Related]
17. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-high resolution mass spectrometric method for the quantification of monomethyl auristatin E (MMAE) and its preclinical pharmacokinetics.
Lee BI; Park MH; Choi J; Shin SH; Byeon JJ; Park Y; Shin YG
Biomed Chromatogr; 2020 Aug; 34(8):e4855. PubMed ID: 32304111
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Liu-Kreyche P; Shen H; Marino AM; Iyer RA; Humphreys WG; Lai Y
Front Pharmacol; 2019; 10():749. PubMed ID: 31379564
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
